Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).

PURPOSE To investigate whether anti-vascular endothelial growth factor therapy with bevacizumab prolongs progression-free survival (PFS) when added to first-line letrozole as treatment of hormone receptor-positive metastatic breast cancer (MBC). PATIENTS AND METHODS Women with hormone receptor-positive MBC were randomly assigned 1:1 in a multicenter, open-label, phase III trial of letrozole (2.5 mg orally per day) with or without bevacizumab (15 mg/kg intravenously once every 3 weeks) within strata defined by measurable disease and disease-free interval. This trial had 90% power to detect a 50% improvement in median PFS from 6 to 9 months. Using a one-sided α = .025, a target sample size of 352 patients was planned. RESULTS From May 2008 to November 2011, 350 women were recruited; 343 received treatment and were observed for efficacy and safety. Median age was 58 years (range, 25 to 87 years). Sixty-two percent had measurable disease, and 45% had de novo MBC. At a median follow-up of 39 months, the addition of bevacizumab resulted in a significant reduction in the hazard of progression (hazard ratio, 0.75; 95% CI, 0.59 to 0.96; P = .016) and a prolongation in median PFS from 15.6 months with letrozole to 20.2 months with letrozole plus bevacizumab. There was no significant difference in overall survival (hazard ratio, 0.87; 95% CI, 0.65 to 1.18; P = .188), with median overall survival of 43.9 months with letrozole versus 47.2 months with letrozole plus bevacizumab. The largest increases in incidence of grade 3 to 4 treatment-related toxicities with the addition of bevacizumab were hypertension (24% v 2%) and proteinuria (11% v 0%). CONCLUSION The addition of bevacizumab to letrozole improved PFS in hormone receptor-positive MBC, but this benefit was associated with a markedly increased risk of grade 3 to 4 toxicities. Research on predictive markers will be required to clarify the role of bevacizumab in this setting.

[1]  S. Paik,et al.  Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. , 2015, The Lancet. Oncology.

[2]  S. Loi,et al.  Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. , 2015, The New England journal of medicine.

[3]  S. Loibl,et al.  Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Agnieszka K. Witkiewicz,et al.  The history and future of targeting cyclin-dependent kinases in cancer therapy , 2015, Nature Reviews Drug Discovery.

[5]  W. Gradishar,et al.  Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103. , 2014 .

[6]  M. Buyse,et al.  Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer , 2013 .

[7]  Steffi Oesterreich,et al.  The search for ESR1 mutations in breast cancer , 2013, Nature Genetics.

[8]  David Chen,et al.  ESR1 ligand binding domain mutations in hormone-resistant breast cancer , 2013, Nature Genetics.

[9]  M. Parmar,et al.  Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. , 2013, The Lancet. Oncology.

[10]  M. Piccart,et al.  Emerging targeted agents in metastatic breast cancer , 2013, Nature Reviews Clinical Oncology.

[11]  Robert B Livingston,et al.  Combination anastrozole and fulvestrant in metastatic breast cancer. , 2012, The New England journal of medicine.

[12]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[13]  M. Piccart,et al.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. , 2012, The New England journal of medicine.

[14]  Tanja Fehm,et al.  Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. , 2012, The New England journal of medicine.

[15]  E. Perez,et al.  RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. D'Agostino.  Changing end points in breast-cancer drug approval--the Avastin story. , 2011, The New England journal of medicine.

[17]  A. Kesselheim,et al.  Reputation and precedent in the bevacizumab decision. , 2011, The New England journal of medicine.

[18]  R. Clarke,et al.  Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. , 2011, Endocrine-related cancer.

[19]  J. Hainsworth,et al.  Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium. , 2011, Clinical breast cancer.

[20]  Xian Zhou,et al.  RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[22]  K. Bland,et al.  Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer. , 2010, Clinical breast cancer.

[23]  Arlene Chan,et al.  Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Gray,et al.  A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). , 2010 .

[25]  Chau Dang,et al.  Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Rongbao Li,et al.  Vascular endothelial growth factor reduces tamoxifen efficacy and promotes metastatic colonization and desmoplasia in breast tumors. , 2008, Cancer research.

[27]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[28]  R. Koos,et al.  Estrogen-induced activation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor expression, and edema in the uterus are mediated by the phosphatidylinositol 3-kinase/Akt pathway. , 2007, Endocrinology.

[29]  R. Schiff,et al.  Unraveling the Mechanisms of Endocrine Resistance in Breast Cancer: New Therapeutic Opportunities , 2007, Clinical Cancer Research.

[30]  Jenny M. Jones,et al.  Chromatin immunoprecipitation analysis of gene expression in the rat uterus in vivo: estrogen-induced recruitment of both estrogen receptor alpha and hypoxia-inducible factor 1 to the vascular endothelial growth factor promoter. , 2005, Molecular endocrinology.

[31]  Anthony Howell,et al.  Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  J. Bergh,et al.  Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers. , 2003, Clinical breast cancer.

[33]  P. Span,et al.  Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma , 2003, Cancer.

[34]  G. Sledge,et al.  A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. , 2003, Seminars in oncology.

[35]  Boris Freidlin,et al.  A comment on futility monitoring. , 2002, Controlled clinical trials.

[36]  A. Buzdar,et al.  Anastrozole is superior to tamoxifen as first‐line therapy in hormone receptor positive advanced breast carcinoma , 2001, Cancer.

[37]  S. Glück.  Anastrozole Is Superior to Tamoxifen as First-Line Therapy in Hormone Receptor Positive Advanced Breast Carcinoma Results of Two Randomized Trials Designed for Combined Analysis , 2001 .

[38]  T. H. van der Kwast,et al.  High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. , 2001, Cancer research.

[39]  C. Boni,et al.  Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  J. Isner,et al.  Estrogen and Angiogenesis: A Review , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[41]  A. Buzdar,et al.  Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[43]  R. Henriksson,et al.  Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  R K Jain,et al.  Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[45]  A. Brodie,et al.  Estrogen regulates vascular endothelial growth/permeability factor expression in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors. , 1996, Endocrinology.

[46]  G. Stancel,et al.  Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen. , 1996, Cancer research.

[47]  B. Hennig,et al.  Antiestrogens inhibit endothelial cell growth stimulated by angiogenic growth factors. , 1996, Anticancer research.

[48]  H. Schnaper,et al.  Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. , 1995, Circulation.

[49]  Xin Huang,et al.  The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. , 2015, The Lancet. Oncology.

[50]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[51]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[52]  A. Bikfalvi,et al.  Tumor angiogenesis , 2020, Advances in cancer research.

[53]  V. Craig Jordan,et al.  In vitro regulation of vascular endothelial growth factor by estrogens and antiestrogens in estrogen-receptor positive breast cancer , 2002, Breast cancer.